Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are newer medications used to treat type 2 diabetes mellitus (T2DM) and obesity. There is growing evidence of a potential association between the use of GLP-1 RAs and non-arteritic anterior ischemic optic neuropathy (NAION). Here, we report a case of NAION in a young patient with diabetes receiving semaglutide (GLP-1 RA), which showed a complete resolution of symptoms after discontinuing the GLP-1 RA. This case adds to growing concerns, given emerging evidence suggesting an increased incidence of NAION among users of GLP-1 RAs. Further studies are required to clarify causality, identify risk factors, and develop monitoring strategies for patients receiving GLP-1 RAs.
Fields of Study & Subjects
Intraoperative Neuromonitoring and Anesthetic Effects
Drug-Induced Ocular Toxicity
Optical Coherence Tomography Applications
Publication details
- Journal / source
- Cureus
- Publisher
- Springer Science and Business Media LLC
- Volume
- 18
- Issue
- 1
- Pages
- e102472–e102472
- Publication date
- 28 January 2026
- Language
- EN